إعلان
إعلان

BDTX

BDTX logo

Black Diamond Therapeutics, Inc. Common Stock

2.81
USD
برعاية
+0.03
+0.94%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

2.83

+0.02
+0.68%

تقارير أرباح BDTX

النسبة الإيجابية المفاجئة

BDTX تفوق 20 من 24 آخر التقديرات.

83%

التقرير التالي

بيانات التقرير القادم
٠٤ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.19
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
+26.67%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-32.14%

Black Diamond Therapeutics, Inc. Common Stock earnings per share and revenue

On ٠٦ نوفمبر ٢٠٢٥, BDTX reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.23 USD, resulting in a 37.32% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.84% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 المحللين forecast an EPS of -0.19 USD, with revenue projected to reach -- USD, implying an زيادة of 26.67% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Black Diamond Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 37.32%, and revenue of $0.00, 0% as expectations.
The stock price moved up 2.84%, changed from $3.87 before the earnings release to $3.98 the day after.
The next earning report is scheduled for ٠٤ مارس ٢٠٢٦.
Based on 11 المحللين, Black Diamond Therapeutics, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان